trial

Improving Work Outcome in People With Recent-onset Schizophrenia

NCTId NCT00203788
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 87 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2006-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
87 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
1999-05
Primary completion
2006-12
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Individual Placement and SupportWorkplace Fundamentals ModuleBrokered Vocational RehabilitationRisperidoneSkills training group

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Keith H. Nuechterlein, PhDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
87
Phase
PHASE4
Primary Completion Date
2006-12
Status
COMPLETED
relationships
The graph out of here
drug
Individual Placement and Support
drug
Workplace Fundamentals Module
drug
Brokered Vocational Rehabilitation
drug
Risperidone
drug
Skills training group
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Keith H. Nuechterlein, PhD
person